路杨于2016年在杭州创立阿诺医药，现任阿诺医药董事长兼首席执行官，主要负责公司战略布局、业务把控及管理。在他的领导下，阿诺医药已组建了一支超过30位资深海归专家组成的管理团队及研发团队，并迅速建立起一条具有国际竞争力的产品管线，已有3款药物进入临床阶段。路杨拥有超过15年的药物开发及商业运营管理经验，在公司战略规划、产品布局、市场开拓、人才引进、资本运作等方面具有战略眼光和丰富经验。在创立阿诺医药前，他曾成功创立2家医药公司，其中一家是国内最早获得多肽DMF受理号并通过FDA认证。路杨毕业于厦门大学，获生物技术学士学位，于中欧国际工商学院获EMBA。路杨曾先后被评为“2018年度杭州创业人物”，“厦门大学生物学科杰出校友”，“厦门大学生物学科百年庆典顾问委员会委员”及“2019医药行业年度新锐人物”。

　　Yang Lu

　　Founder, President and CEO, Adlai Nortye

　　Yang Lu founded Adlai Nortye in 2016, currently he is Founder, President and Chief Executive Officer. Under his leadership, Adlai Nortye has established the executive and R&D team composed of more than 30 senior returnee experts, and has built a competitive pipeline from preclinical to clinical stage. With more than 15 years of experience in drug development and commercial operations management, Yang Lu has a strategic vision in planning, business development and capital management. Prior to founding Adlai Nortye, Yang Lu has successfully established two pharmaceutical companies, one of which was the first to obtain the polypeptide drug master file’s number from NMPA and the approval from FDA. Yang Lu obtained his B.S in Biology from Xiamen University and an EMBA from China Europe International Business School.■